Výsledky vyhledávání - "Peter, Amlot"

Establishment and Characterization of a Bank of Cytotoxic T Lymphocytes for Immunotherapy of Epstein-Barr Virus-Associated Diseases

Autor: Dorothy H. Crawford, Marie M. Jones, David C. Kilpatrick, Peter Amlot, Marc Turner, Gwen Wilkie, Clare Taylor, Tanzina Haque, David M Burns

Publikováno v: Journal of Immunotherapy. 27:309-316

Adoptive immunotherapy using Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes (CTL) generated ex vivo can be an effective treatment of EBV-positive posttransplantation lymphoproliferative disease (PTLD). We describe the establishment of a cr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1c52d5e192d9a5855a459a7ebbc5a9f
https://doi.org/10.1097/00002371-200407000-00007

Zobrazit plný text záznamu

Effect of anti-CD20 (rituximab) on resistant thrombocytopenia in autoimmune lymphoproliferative syndrome

Autor: Atul Mehta, Vincent J Tormey, Bridget T. Heelan, Peter Amlot, A. David B. Webster, Elspeth Payne

Publikováno v: British Journal of Haematology. 118:1078-1081

Fas (CD95) plays an important role in apoptosis. Patients with defects in Fas have an autoimmune lymphoproliferative syndrome (ALPS) characterized by lymphadenopathy, autoimmune cytopenias and an increased incidence of lymphomas. There are approximat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::44ef4ff6681b8bfc136816e2a73ffedb
https://doi.org/10.1046/j.1365-2141.2002.03753.x

Zobrazit plný text záznamu

Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells

Autor: Gwen Wilkie, Clare Taylor, Anthony J. Swerdlow, Dorothy H. Crawford, Dilani Dombagoda, Parvez Murad, Kate M Britton, Tanzina Haque, Peter Amlot, Angela Iley

Publikováno v: The Lancet. 360:436-442

Summary Background Epstein-Barr virus (EBV)-associated posttransplantation lymphoproliferative disease (PTLD) is a common, often fatal, complication of bone-marrow and solidorgan transplantation. Since tumour growth results from inadequate T-cell con

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00df52f97b9923bd4c47dffab95574a1
https://doi.org/10.1016/s0140-6736(02)09672-1

Zobrazit plný text záznamu

Plný text ve formátu HTML

COMPLETE REGRESSION OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE USING PARTIALLY HLA-MATCHED EPSTEIN BARR VIRUS-SPECIFIC CYTOTOXIC T CELLS1

Autor: Tanzina Haque, Gwen Wilkie, Parvez Murad, Dorothy H. Crawford, Peter Amlot, Sue V. Beath, Patrick J. McKiernan, Clare Taylor

Publikováno v: Transplantation. 72:1399-1402

Background Adoptive immunotherapy with autologous and donor-derived cytotoxic T lymphocytes (CTL) has recently been used to treat Epstein Barr virus (EBV)-positive posttransplant lymphoproliferative disease (PTLD). Methods and results We report compl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b668ce9ee39ecc9d4d346f4adb5abca2
https://doi.org/10.1097/00007890-200110270-00012

Zobrazit plný text záznamu

Follicular dendritic cells share a membrane-bound protein with fibroblasts

Autor: Margarita Bofill, Arne N. Akbar, Peter Amlot

Publikováno v: The Journal of Pathology. 191:217-226

The expression of a fibroblast antigen (AS02) on a proportion of CD21+ follicular dendritic cells (FDCs) provides evidence in support of their fibroblastic reticular origin. This antigen is expressed on the membrane of tissue fibroblasts but is absen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::93c8063e6faecfd60dc8aabfae51a946
https://doi.org/10.1002/(sici)1096-9896(200006)191:2<217::aid-path586>3.0.co

Zobrazit plný text záznamu

A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy

Autor: Peter Amlot, J. W. Uhr, James A. Richardson, Ellen S. Vitetta, David Cunningham, M. McCarthy, Richard D. May, Victor Ghetie, Joseph W. Fay, Octavio Ramilo, Philip E. Thorpe, Robert H. Collins, Joseph T. Newman, Marvin J. Stone

Publikováno v: Blood. 82:2624-2633

Twenty-six patients, whose B-cell lymphoma had relapsed after conventional therapies, were treated in a phase I dose escalation study with an immunotoxin consisting of a mouse CD22 monoclonal antibody (RFB4:IgG1K) coupled to chemically deglycosylated

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::56508b6105b2e6fa7a1b7f8302444bab
https://doi.org/10.1182/blood.v82.9.2624.bloodjournal8292624

Zobrazit plný text záznamu

A Phase I Clinical Trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma

Autor: Philip Ross, Peter Amlot, Pei-San Chan, Christopher McNamara, Alan G. Ramsay, T. Andrew Lister, Alessandra Malaroda, Surinder K. Sharma, John R. Buscombe, Anmol Malhotra, Shokri Othman, Richard H. J. Begent, John Violet, Gairin Dancey, Roslyn J. Francis, Nicholas Woodward, Sweta Parker, Alan J. Green, Natalie Griffin

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 15(24)

Purpose: There is a need for new treatments for Hodgkin and T-cell lymphoma due to the development of drug resistance in a proportion of patients. This phase I study of radioimmunotherapy used CHT-25, a chimeric antibody to the α-chain of the interl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3576f9fa8b941a8801d61b10457bb499
https://pubmed.ncbi.nlm.nih.gov/20008855

Zobrazit plný text záznamu

IMMUNOHISTOLOGY OF EPSTEIN-BARR VIRUS-ASSOCIATED ANTIGENS IN B CELL DISORDERS FROM IMMUNOCOMPROMISED INDIVIDUALS

Autor: Magdi H. Yacoub, Jennie L. Thomas, Peter Amlot, Marlene L. Rose, Dorothy H. Crawford, Martin J. Allday, Neil A. Hotchin

Publikováno v: Europe PubMed Central

Proliferating B cell lesions developing in a series of immunosuppressed organ transplant recipients and patients with X-linked lymphoproliferative syndrome were examined for Epstein-Barr virus and cellular gene expression using immunocytochemistry an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec47b2d13149c70b747aa4036fa33e36
https://doi.org/10.1097/00007890-199005000-00022

Zobrazit plný text záznamu

A quantitative assay for Epstein-Barr Virus-specific immunity shows interferon-gamma producing CD8+ T cells increase during immunosuppression reduction to treat posttransplant lymphoproliferative disease

Autor: Eira Rawlings, Amy E. Guppy, Peter Amlot, Linda Barber, J. Alejandro Madrigal

Publikováno v: Transplantation. 84(11)

Reduction of immunosuppression (RIS) to allow development or recovery of Epstein-Barr virus (EBV) immunity can be used to treat EBV-associated posttransplant lymphoproliferative disease (PTLD). Quantification of EBV-specific immunity would help asses

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79ca32014fa823d9357b3b9b713680f0
https://pubmed.ncbi.nlm.nih.gov/18091531

Zobrazit plný text záznamu

Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT)

Autor: Nigel P. Minton, Des Purdy, Surinder K. Sharma, Richard H. J. Begent, Peter Amlot, G Tharakan, Berend Tolner, A Mayer, KA Chester

Publikováno v: British Journal of Cancer
Europe PubMed Central

Carboxypeptidase G2 (CP) is a bacterial enzyme, which is targeted to tumours by an antitumour antibody for local prodrug activation in antibody-directed enzyme prodrug therapy (ADEPT). Repeated cycles of ADEPT are desirable but are hampered by human

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee8896ff0f386f00997480a6ff5528ee
https://pubmed.ncbi.nlm.nih.gov/15162148

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání